TALNETANT
Talnetant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target neuromedin-K receptor and substance-K receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
No data
Commercial
No data
Clinical
No data
Drug
General
| Drug common name | TALNETANT |
| INN | talnetant |
| Description | Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several functions (primarily treatment of irritable bowel syndrome, despite a 2007 study finding no statistically significant improvement in rectal hypersensitivity over placebo). Its use as a potential antipsychotic drug for the treatment of schizophrenia has also been discontinued.
|
| Classification | Small molecule |
| Drug class | tachykinin (neurokinin) receptor antagonists: NK3 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 174636-32-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL10188 |
| ChEBI ID | — |
| PubChem CID | 133090 |
| DrugBank | — |
| UNII ID | CZ3T9T146K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TACR3
TACR3
TACR2
TACR2
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use